Investigator's Choice
Sponsors
Pfizer, Clavis Pharma, AiCuris Anti-infective Cures AG, Merus B.V., Tarapeutics Science Inc.
Conditions
Acute Myeloid Leukemia (AML)HSV InfectionHead and Neck Squamous Cell CarcinomaLymphomaNK T-Cell LymphomaPTCL
Phase 3
Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)
CompletedNCT00117598
Start: 2005-05-31End: 2011-01-31Updated: 2015-03-30
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
CompletedNCT01147939
Start: 2010-06-30End: 2013-06-30Updated: 2013-09-27
Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects
CompletedNCT03073967
Start: 2017-05-08End: 2025-11-11Updated: 2026-06-12
A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
Active, not recruitingNCT06496178
Start: 2024-06-25End: 2029-03-01Updated: 2026-08-31
TR115 VS Investigator's Choice in Relapsed/Refractory Peripheral T/NK Cell Lymphoma
Not yet recruitingNCT07639879
Start: 2026-07-30End: 2030-07-30Target: 180Updated: 2026-06-10